tirzepatide clinical trial enrollment as Compared with Semaglutide for the Treatment of Obesity Reduction of prevalence of patients
Description
How It Works Compounded Tirzepatide (GLP-1/GIP) is a once-weekly injectable therapy that mimics dual incretin hormones, potentially offering stronger support for appetite regulation and metabolic balance than GLP-1 alone
The trial, which seeks to enroll 1,000 long COVID patients nationwide, will explore how self-administration of tirzepatide, Eli Lillys GLP-1 agonist marketed as Mounjaro for diabetes treatment and Zepbound for weight loss, affects symptoms over a 12-month period
When tirzepatide activates GLP-1 receptors, it stimulates glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and reduces appetite through central pathways in the hypothalamus
Typical pricing: /month
